How type i interferons work in multiple sclerosis and other diseases: Some unexpected mechanisms

Journal of Interferon and Cytokine Research

Volumn 34, Issue 8, 2014, Pages 589-599

  Reder, Anthony T ^a   Feng, Xuan ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA INTERFERON; CORTICOTROPIN; HISTAMINE H2 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUTRALIZING ANTIBODY; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E2; VITAMIN D; INTERFERON;

ARTHRALGIA; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LEUKEMIA; BODY WEIGHT DISORDER; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DEPRESSION; DRUG EFFECT; DRUG RECEPTOR BINDING; FATIGUE; FOLLICULAR LYMPHOMA; GLIOMA; HEPATITIS B; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; IMMUNE COMPLEX NEPHRITIS; IMMUNOREGULATION; IMMUNOTHERAPY; KAPOSI SARCOMA; MELANOMA; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYALGIA; MYCOSIS FUNGOIDES; NEOPLASM; NEUROTOXICITY; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; REVIEW; SKIN CANCER; SYSTEMIC THERAPY; THROMBOCYTOPENIA; VASCULAR DISEASE; VIRUS INFECTION; VITAMIN SUPPLEMENTATION; ANIMAL; COMPLICATION; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; IMMUNOLOGY; PROCEDURES; RISK ASSESSMENT;

ANIMALS; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE I; MULTIPLE SCLEROSIS; RISK ASSESSMENT;

EID: 84905404962     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2013.0158     Document Type: Review

References (108)

1. Ahn J, Feng X, Patel N, Dhawan N, Reder AT. 2004. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-b therapy: implications for control of apoptosis. Front Biosci 9:1547-1555.
2. Aivo J, Lindsröm BM, Soilu-Hänninen M. 2012. A Randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Mult Scler Int 2012:802796.
3. Amezcua L, Axtell RC, Cen S, Tauhid S, Neema M, Subhani D, Bakshi R, Steinman L, Berkovich R. 2013. Pilot study of monthly pulse adrenocorticotropic hormone or methylpred-nisolone as an add-on therapy to b-interferons for long-term treatment of multiple sclerosis. ECTRIMS (online), P1097.
4. Anlar B, Gücüyener K, Imir T, Yalaz K, Renda Y. 1993. Cimetidine as an immunomodulator in subacute sclerosing panencephalitis: a double blind, placebo-controlled study. Pediatr Infect Dis J 12:578-581.
5. Antel JP, Arnason BGW, Medof ME. 1979. Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann Neurol 5:338-342.
6. Antel JP, Freedman MS, Brodovsky S, Francis GS, Duquette P. 1989. Activated suppressor cell function in severely disabled patients with multiple sclerosis. Ann Neurol 25:204-207.
7. Arnason BG, Berkovich R, Catania A, Lisak RP, Zaidi M. 2012. Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult Scler 19:130-136.
8. Arscott WT, Soltys J, Knight J, Mao-Draayer Y. 2011. Interferon b-1b directly modulates human neural stem/progenitor cell fate. Brain Res 1413:1-8.
9. Ascherio A, Munger KL, White R, Kochert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Mon-talban X, Edan G, Barkhof F, Pleimes D, Radu EW, Sandbrink R, Kapos L, Pohl C. 2014. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurology 71:306-314.
10. Aström KE, Webster HDF, Arnason BGW. 1968. The initial lesion in experimental allergic neuritis: a phase and electron microscopic study. J Exp Med 128:469-495.
11. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C. 2010. T helper type 1 and 17 cells determine efficacy of interferon-b in multiple sclerosis and experimental encephalomyelitis. Nat Med 16:406-413.
12. Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, Landin R. 2010. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology 74:1033-1040.
13. Bazer FW. 2013. Pregnancy recognition signaling mechanisms in ruminants and pigs. J Anim Sci Biotechnol 4:23.
14. Berger JR, Sheremata WA, Resnick L, Atherton S, Fletcher MA, Norenberg M. 1989. Multiple sclerosis-like illness occurring with human immunodeficiency virus infection. Neurology 39:324-329.
15. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder A. 2008. Combining beta interferon and atorvastatin increases disease activity in multiple sclerosis. Neurology 71:1390-1395.
16. Buyon JP. 2008. Systemic lupus erythematosus. In: Klippel JH, editor. Primer on Rheumatic Diseases (Chapter 15). New York, NY: Springer Science+Business Media, pp 303-337.
17. Byskosh PV, Reder AT. 1996. Interferon-b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler 1:262-269.
18. Cabrera-Gomez JA, Lopez-Saura P. 1999. [Recent advances in the treatment the nervous system disorders with interferonalpha]. Rev Neurol 29:1225-1235.
19. Camenga DL, Johnson KP, Alter M, Engelhardt CD, Fishman PS, Greenstein JI, Haley AS, Hirsch RL, Kleiner JE, Kofie VY, Koski CL, Margulies SL, Panitch HS, Valero R. 1986. Systemic recombinant a-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol 43:1239-1246.
20. Chen M, Chen G, Deng S, Liu X, Hutton GJ, Hong J. 2012. IFN-b induces the proliferation of CD4+ CD25 + Foxp3 + regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis. J Neu-roimmunol 242:39-46
21. Chon TW, Bixler S. 2010. Interferon-t: current applications and potential in antiviral therapy. J Interferon Cytokine Res 30:477-485.
22. Comabella M, Lunemann JD, Rio J, Sanchez A, Lopez C, Julia E, Fernandez M, Nonell L, Camina-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M, Montalban X, Martin R. 2009. A type I interferon signature in monocytes is associated with poor response to interferon-b in multiple sclerosis. Brain 132(Pt 12):3353-3365.
23. Correale J, Farez MF, Ysrraelit MC. 2012. Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol 72:682-694.
24. Correale J, Villa A. 2008. Isolation and characterization of CD8+ regulatory T cells in multiple sclerosis. J Neuro-immunol 195:121-134.
25. Croze E, Velichko S, Tran T, Yamaguchi K, Salamon H, Reder A, Knappertz V, Paz P. 2009. Betaferon" induces a novel alternate start transcript in cells obtained from relapsing-remitting multiple sclerosis patients and human brain that is associated with control of oxidative resistance. Mult Scler 15(Suppl 2):P475, S138.
26. Croze E, Yamaguchi KD, Knappertz V, Reder AT, Salamon H. 2013. Interferon-beta-1b-induced short-and long-term signatures of treatment activity in multiple sclerosis. Pharma-cogenomics J 13:443-451.
27. Dalla Libera D, Di Mitri D, Bergami A, Centonze D, Gasperini C, Grasso MG, Galgani S, Martinelli V, Comi G, Avolio C, Martino G, Borsellino G, Sallusto F, Battistini L, Furlan R. 2011. T regulatory cells are markers of disease activity in multiple sclerosis patients. PLoS One 6:e21386.
28. Der SD, Zhou A, Williams BR, Silverman RH. 1998. Identification of genes differentially regulated by interferon a, b, or g using oligonucleotide arrays. Proc Natl Acad Sci USA 95:15623-15628.
29. Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R, Ferrio MF, Bradac GB, Riva A, Vai S, Geuna M, Bergamini L, Bergamasco B. 1994. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 44:406-413.
30. Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F. 2009. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-b. Ann Neurol 65:499-509.
31. Duschet P, Schwarz T, Soyer P, Henk A, Hausmaninger H, Gschnait F. 1988. Treatment of herpes zoster. Recombinant alpha interferon versus acyclovir. Int J Dermatol 27:193-197.
32. Ebers GC, PRISMS (Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis) Study Group. 1998. Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504.
33. Feng X, Anzai L, Abdallah M, Kim H-I, Li L, Reder AT. 2013. Serum cytokines, neuroprotective proteins, and interferon signaling in IFN therapy responders (R) and non-responders (NR) in MS. Neurology 80 (Meeting Abstracts 1), P05.182. Available at www.neurology.org online
34. Feng X, Han D, Kilaru BK, Franek BS, Niewold TB, Reder AT. 2012a. Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins. Arch Neurol 69:1303-1309.
35. Feng X, Petraglia AL, Chen M, Byskosh PV, Boos MD, Reder AT. 2002a. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol 129:105-115.
36. Feng X, Reder NP, Yanamandala M, Hill A, Franek BS, Niewold TB, Reder AT, Javed A. 2012b. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci 313:48-53.
37. Feng X, Yau D, Holbrook C, Reder AT. 2002b. Type I interferons inhibit Interleukin-10 production in activated human monocytes and stimulate IL-10 in T cells: implications for Th1-mediated diseases. J Interferon Cytokine Res 22:311-319.
38. Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BG, Kappos L, Goodin D, Jeffery D, Hartung HP, Comi G, Wolinsky JS, Bogumil T, Pohl C, Beckmann K, Sandbrink R, Croze E, Brown C, Desimone TM, Arnold DL, Cutter G, Knappertz V. 2011. Interferon b-1b and glatiramer acetate effects on permanent black hole evolution. Neurology 76:1222-1228.
39. Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Goodkin DE, et al. 2000. Neuropsychological effects of interferon b-1a in relapsing multiple sclerosis. Ann Neurol 48:885-892.
40. Foster GR, Masri SH, David R, Jones M, Datta A, Lombardi G, Runkell L, de Dios C, Sizing I, James MJ, Marelli-Berg FM. 2004. IFN-a subtypes differentially affect human T cell motility. J Immunol 173:1663-1670.
41. Frith J, the AUSTIMS Research Group. 1989. Interferon-a and transfer factor in the treatment of multiple sclerosis: a doubleblind, placebo-controlled trial. J Neurol Neurosurg Psychiatry 52:566-574.
42. Garcin G, Bordat Y, Chuchana P, Monneron D, Law HK, Piehler J, Uze G. 2013. Differential activity of type I interferon subtypes for dendritic cell differentiation. PLoS One 8:e58465.
43. Goelz SE, Hahm B, Luo Y, Engber T, Gorelik L. 2007. Positive regulation of neuroprotective genes in the CNS of mice with experimental autoimmune encephalitis (EAE) by interferon beta (IFN-b) treatment. Neurology 68(Suppl 1):P03.031A.
44. Gold SM, Voskuhl RR. 2009. Estrogen and testosterone therapies in multiple sclerosis. Prog Brain Res 175:239-251.
45. Goodin DS, Hurwitz B, Noronha A. 2007. Neutralizing antibodies to interferon b-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res 35:173-187.
46. Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V. 2012. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNb-1b trial. Neurology 78:1315-1322.
47. Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, Mills JA, Weiner HL. 1983. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308:178-180.
48. Hedrich CM, Rauen T, Kis-Toth K, Kyttaris VC, Tsokos GC. 2012. cAMP-responsive element modulator a (CREMa) suppresses IL-17F protein expression in T lymphocytes from patients with systemic lupus erythematosus (SLE). J Biol Chem 287:4715-4725.
49. Idzko M, la Sala A, Ferrari D, Panther E, Herouy Y, Dichmann S, Mockenhaupt M, Di Virgilio F, Girolomoni G, Norgauer J. 2002. Expression and function of histamine receptors in human monocyte-derived dendritic cells. J Allergy Clin Immunol 109:839-846.
50. Ishizuka T, Murotani T, Yamatodani A. 2012. Action of mod-afinil through histaminergic and orexinergic neurons. Vitam Horm 89:259-278.
51. Jaitin DA, Roisman LC, Jaks E, Gavutis M, Piehler J, Van der Heyden J, Uze G, Schreiber G. 2006. Inquiring into the differential action of interferons (IFNs): an IFN-a2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-b. Mol Cell Biol 26:1888-1897.
52. Javed A, Balabanov R, Arnason BGW, Kelly TJ, Sweiss NJ, Pytel P, Walsh R, Blair EA, Stemer A, Lazzaro M, Reder AT. 2008. Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler 14:809-814.
53. + T cell responses in patients with multiple sclerosis. J Clin Invest 109:641-649.
54. Karaszewski JW, Reder AT, Anlar B, Arnason BGW. 1993. Increased high affinity beta-adrenergic receptor densities and cyclic AMP responses of CD8 cells in multiple sclerosis. J Neuroimmunol 43:1-7.
55. Khorooshi R, Owens T. 2010. Injury-induced type I IFN signaling regulates inflammatory responses in the central nervous system. J Immunol 185:1258-1264.
56. Khoury SJ, Healy BC, Kivisakk P, Viglietta V, Egorova S, Guttmann CR, Wedgwood JF, Hafler DA, Weiner HL, Buckle G, Cook S, Reddy S. 2010. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol 67:1055-1061.
57. Knobler RL, Greenstein JI, Johnson KP, Lublin FD, Panitch HS, Conway K, Grant-Gorsen SV, Muldoon J, Marcus SG, Wallenberg JC. 1993. Systemic recombinant human interferon-b treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 13:333-340.
58. Knobler RL, Panitch HS, Braheny SL, Sipe JC, Rice GPA, Huddlestone JR, Francis GS, Hooper CJ, Kamin-Lewis RM, Johnson KP, Oldstone MBA, Merigan TC. 1984. Systemic alpha-interferon therapy of multiple sclerosis. Neurology 34:1273-1279.
59. Lacy M, Hauser M, Pliskin N, Assuras S, Valentine MO, Reder A. 2013. The effects of long-term interferon-b-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler 19:1765-1772.
60. Li X, Murray F, Koide N, Goldstone J, Dann SM, Chen J, Bertin S, Fu G, Weinstein LS, Chen M, Corr M, Eckmann L, Insel PA, Raz E. 2012. Divergent requirement for Gas and cAMP in the differentiation and inflammatory profile of distinct mouse Th subsets. J Clin Invest 122:963-973.
61. Lucas RM, Ponsonby AL, Dear K, Valery PC, Pender MP, Taylor BV, Kilpatrick TJ, Dwyer T, Coulthard A, Chapman C, van der Mei I, Williams D, McMichael AJ. 2011. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 76:540-548.
62. 2-dependent mechanism. J Immunol 177:246-254.
63. Marie I, Durbin JE, Levy, DE. 1998. Differential viral induction of distinct interferon-a genes by positive feedback through interferon regulatory factor-7. EMBO J 17:6660-6669.
64. Michel L, Foucher Y, Vukusic S, Confavreux C, de Seze J, Brassat D, Clanet M, Clavelou P, Ouallet JC, Brochet B, Pelletier J, Labauge P, Lebrun C, Lepage E, Le Frere F, Jacq-Foucher M, Barriere P, Wiertlewski S, Laplaud DA. 2012. Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry 83:796-802.
65. Moll HP, Freudenthaler H, Zommer A, Buchberger E, Brostjan C. 2008. Neutralizing type I IFN antibodies trigger an IFN-like response in endothelial cells. J Immunol 180:5250-5256.
66. Moll HP, Freudenthaler H, Zommer A, Buchberger E, Lin XH, Crisafulli S, Pandya Y, Pestka S, Lavoie T, Brostjan C. 2011. Contamination with recombinant IFN accounts for the unexpected stimulatory properties of commonly used IFN-blocking antibodies. Eur J Immunol 41:252-254.
67. Moraga I, Harari D, Schreiber G, Uzé G, Pellegrini S. 2009. Receptor density is key to the alpha2/beta interferon differential activities. Mol Cell Biol 29:4778-4787.
68. Mosenden R, Tasken K. 2011. Cyclic AMP-mediated immune regulation-overview of mechanisms of action in T cells. Cell Signal 23:1009-1016.
69. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. 2006. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296:2832-2838.
70. Nakashima I, Fujihara K, Kimpara T, Okita N, Takase S, Itoyama Y. 2001. Linear pontine trigeminal root lesions in multiple sclerosis: clinical and magnetic resonance imaging studies in 5 cases. Arch Neurol 58:101-104.
71. Nexo BA, Pedersen L, Sorensen HT, Koch-Henriksen N. 2013. Treatment of HIV and risk of multiple sclerosis. Epidemiology 24:331-332.
72. Noronha A, Toscas A, Jensen M. 1992. Contrasting effects of alpha, beta, and gamma interferons on nonspecific suppressor function in multiple sclerosis. Ann Neurol 31:103-106.
73. Ostensen M, Brucato A, Carp H, Chambers C, Dolhain RJ, Doria A, Forger F, Gordon C, Hahn S, Khamashta M, Lockshin MD, Matucci-Cerinic M, Meroni P, Nelson JL, Parke A, Petri M, Raio L, Ruiz-Irastorza G, Silva CA, Tin-cani A, Villiger PM, Wunder D, Cutolo M. 2011. Pregnancy and reproduction in autoimmune rheumatic diseases. Rheumatology (Oxford) 50:657-664.
74. Panitch HS. 1994. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 36(Suppl):S25-S28.
75. Panitch HS. 2004. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63: 1788-1795.
76. Passani MB, Ballerini C. 2012. Histamine and neuroinflammation: insights from murine experimental autoimmune encephalomyelitis. Front Syst Neurosci 6:32.
77. Perron H, Germi R, Bernard C, Garcia-Montojo M, Deluen C, Farinelli L, Faucard R, Veas F, Stefas I, Fabriek BO, Van-Horssen J, Van-der-Valk P, Gerdil C, Mancuso R, Saresella M, Clerici M, Marcel S, Creange A, Cavaretta R, Caputo D, Arru G, Morand P, Lang AB, Sotgiu S, Ruprecht K, Rieck-mann P, Villoslada P, Chofflon M, Boucraut J, Pelletier J, Hartung HP. 2012. Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler 18:1721-1736.
78. Petersen T, Møller-Larsen A, Ellermann-Eriksen S, Thiel S, Christensen T. 2012. Effects of interferon-beta therapy on elements in the antiviral immune response towards the human herpesviruses EBV, HSV, and VZV, and to the human endogenous retroviruses HERV-H and HERV-W in multiple sclerosis. J Neuroimmunol 249:105-108.
79. Petzold A, Mondria T, Kuhle J, Rocca MA, Cornelissen J, te Boekhorst P, Lowenberg B, Giovannoni G, Filippi M, Kappos L, Hintzen R. 2010. Evidence for acute neurotoxicity after chemotherapy. Ann Neurol 68:806-815.
80. Pliskin NH, Hamer DP, Goldstein DS, Towle VL, Reder AT, Noronha A, Arnason BGW. 1996. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon b-1b. Neurology 47:1463-1468.
81. Reder AT. 2007. Neutralizing antibodies in multiple sclerosis: a complex impact on interferon responses, magnetic resonance imaging findings, and clinical outcomes. Mul Scler 13(Suppl): 553-562.
82. Reder AT, Abdallah N, Kim H-I, Anzai L, Li L, Feng X. 2013. Correction of non-response to interferon-beta in multiple sclerosis. Neurology 80 (Meeting Abstracts 1), P01.203. Available at www.neurology.org
83. Reder AT, Arnason BGW. 1995. Trigeminal neuralgia in MS relieved by a prostaglandin E analogue. Neurology 45:1097-1100.
84. Reder AT, Feng X. 2013. Aberrant type I interferon regulation in autoimmunity: opposite directions in MS and SLE, shaped by evolution and body ecology. Front Immunol 4:1-13.
85. Reder AT, Li L, Feng X. 2011. Disease activity affects responses to IFN-b-1b therapy in multiple sclerosis. Neurology 76(Suppl. 3):P01.215.
86. Reder AT, Thapar M, Sapugay AM, Jensen MA. 1994. Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J Neuro-immunol 54:117-127.
87. Reyes-Vazquez C, Prieto-Gomez B, Dafny N. 2012. Interferon modulates central nervous system function. Brain Res 1442: 76-89.
88. Roberts RM. 2007. Interferon-tau, a type 1 interferon involved in maternal recognition of pregnancy. Cytokine Growth Factor Rev 18:403-408.
89. Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW, Dixon WJ, Foley JM, Geschwind N, MacKay RP, McDowell FH, Scheinberg LC, Schumacher GA, White PT, Brown AJ, Fusillo MG, Johnson W, Kane CA, Lee JE, de Oliveira MM, Rumberg J, Simpson JF. 1970. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs. placebo: final report. Neurology 20:1-70.
90. Rudick RA, Rani MR, Xu Y, Lee JC, Na J, Shrock J, Josyula A, Fisher E, Ransohoff RM. 2011. Excessive biologic response to IFNb is associated with poor treatment response in patients with multiple sclerosis. PLoS One 6:e19262.
91. Sadzak I, Schiff M, Gattermeier I, Glinitzer R, Sauer I, Saal-muller A, Yang E, Schaljo B. 2008. Recruitment of Stat1 to chromatin is required for interferon-induced serine phos-phorylation of Stat1 transactivation domain. Proc Natl Acad Sci U S A 105:8944-8949.
92. Sahasrabudhe DM, McCune CS, O'Donnell RW, Henshaw EC. 1987. Inhibition of suppressor T lymphocytes (Ts) by ci-metidine. J Immunol 138:2760-2763.
93. Sansoni P, Silverman ED, Khan MM, Melmon KL, Engleman EG. 1985. Immunoregulatory T cells in man. Histamine-induced suppressor T cells are derived from a Leu 2+ (T8+) subpopulation distinct from that which gives rise to cytotoxic T cells. J Clin Invest 75:650-656.
94. Sibley WA, Bamford CR, Clark K. 1985. Clinical viral infections and multiple sclerosis. Lancet I:1313-1315.
95. Soilu-Hanninen M, Aivo J, Lindstrom BM, Elovaara I, Sume-lahti ML, Farkkila M, Tienari P, Atula S, Sarasoja T, Herrala L, Keskinarkaus I, Kruger J, Kallio T, Rocca MA, Filippi M. 2012. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 83:565-571.
96. Squillacote D, Martinez M, Sheremata W. 1996. Natural alpha interferon in multiple sclerosis: results of three preliminary series. J Int Med Res 24:246-257.
97. Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, Egan GF, Mitchell PJ, Harrison LC, Butzkueven H, Kilpatrick TJ. 2011. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 77: 1611-1618.
98. Stewart N, Simpson S Jr., van der Mei I, Ponsonby AL, Blizzard L, Dwyer T, Pittas F, Eyles D, Ko P, Taylor BV. 2012. Interferon-b and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 79:254-260.
99. Talpaz M, Hehlmann R, Quintas-Cardama A, Mercer J, Cortes J. 2013. Re-emergence of interferon-a in the treatment of chronic myeloid leukemia. Leukemia 27:803-812.
100. Taylor AW, Kitaichi N. 2008. The diminishment of experimental autoimmune encephalomyelitis (EAE) by neuropeptide alpha-melanocyte stimulating hormone (a-MSH) therapy. Brain Behav Immun 22:639-646.
101. Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, Lee C, Yarden G, Vleck SE, Glenn JS, Nolan GP, Piehler J, Schreiber G, Garcia KC. 2011. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 146:621-632.
102. van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, Taylor BV, Butzkueven H, Kilpatrick T. 2003. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 327:316.
103. bright natural killer cells and CD4 + CD25 + Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol 215:125-128.
104. high regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 123:79-89.
105. Vitale G, de Herder WW, van Koetsveld PM, Waaijers M, Schoordijk W, Croze E, Colao A, Lamberts SW, Hofland LJ. 2006. IFN-b is a highly potent inhibitor of gastro-enteropancreatic neuroendocrine tumor cell growth in vitro. Cancer Res 66:554-562.
106. Vitale G, van Eijck CH, van Koetsveld Ing PM, Erdmann JI, Speel EJ, van der Wansem Ing K, Mooij DM, Colao A, Lombardi G, Croze E, Lamberts SW, Hofland LJ. 2007. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg 246:259-268.
107. Voskuhl R, Wang HJ, Wu TCJ, Sicotte N, Bates A, Beaver G, Corboy J, Cross A, Dhib-Jalbut S, Ford C, Giesser B, Jacobs D, Lynch S, Pachner A, Racke M, Ratchford J, Reder AT, Rose J, Wingerchuk D, Burnett M, Tseng CH, Elashoff R. 2014. A combination trial of estriol plus glatimer acetate in relapsing-remitting multiple sclerosis. Neurology (Meeting Abstracts 1), S23.003. Available at www.neurology.org online
108. Wiegmann K, Muthyala S, Kim DH, Arnason BGW, Chelmicka-Schorr E. 1995. b-Adrenergic agonists suppress chronic/relapsing experimental allergic encephalomyelitis (CREAE) in Lewis rats. J Neuroimmunol 56:201-206.